Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.75 |
| ▸ | HTR1A | P08908 | 3/20 | 0.75 |
| ▸ | HTR2A | P28223 | 4/20 | 0.74 |
| ▸ | BCHE | P06276 | 6/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HTR1E | P28566 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970873 | 1.00 | HTR6 (0.75) | HTR6HTR1AHTR2ABCHEHTR2C | |
| SCHEMBL23996887 | 0.94 | HTR1A (0.71) | HTR6HTR1AHTR2ABCHEHTR2C | |
| SCHEMBL1118996 | 0.91 | HTR2A (0.88) | HTR6HTR1AHTR2ABCHEHTR2C | |
| SCHEMBL21073587 | 0.87 | HTR2A (0.68) | HTR6HTR1AHTR2ABCHEHTR2C | |
| Diethyltryptamine SCHEMBL517713 | 0.86 | HTR1A (1.00) | HTR6HTR1AHTR2ABCHEHTR2C | |
| SCHEMBL22027268 | 0.85 | HTR2A (1.00) | HTR6HTR1AHTR2ABCHEHTR2C | |
| Diethyltryptamine SCHEMBL22462319 | 0.84 | HTR1A (0.97) | HTR6HTR1AHTR2AHTR2CHTR2B | |
| Tryptamine SCHEMBL22800107 | 0.84 | HTR2A (0.77) | HTR6HTR1AHTR2ABCHEHTR2C | |
| SCHEMBL266641 | 0.84 | SLC6A4 (0.68) | HTR6HTR1AHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7869119 | 0.82 | TRPM8 (0.72) | HTR6HTR1AHTR2ABCHEHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4452986-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| CN-118055766-A | Magic and non-magic serotonin receptor agonist and its preparing process and usage | 库莱恩有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4313007-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | Lyfe CHNG, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023225043-A1 | TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4251181-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251139-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022221072-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022212789-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3994458-A1 | ARYLALKYLAMINE, PYRROLE, INDOLE AND OPIATE DERIVATIVE CONCENTRATION DETERMINATION METHOD AND TEST KIT USING SAID METHOD | Blei, Felix (DE) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | HTR6 5/4885HTR1A 3/4885HTR2A 8/4885 |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | HTR6 7/4885HTR1A 10/4885HTR2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.